Chemometec pursues cell therapy companies with tailored instrument

Chemometec's newest cell analysis instrument, which was launched in January, spearheads the company's all-important strategy to deliver instruments to biotech companies involved in cell therapy. Analyst points out the company as a potential acquisition target.

Foto: Kevin Grønnemann/MedWatch

Michael Eising, CEO of Cemometec, has asked the company's sales people to aim all efforts towards one goal: the Danish company must be the leading supplier of instruments for counting and analyzing cells at those biotech companies that are currently struggling to develop cell therapies.

In order to meet that goal, Chemometec has developed a new cell analysis instrument named Xcyto 5 in just about a year, and the instrument is tailored towards cell therapy companies.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier